期刊文献+
共找到10篇文章
< 1 >
每页显示 20 50 100
宫颈晚期癌采用5-FU局部多点注射联合TP方案新辅助化疗的观察与护理 被引量:3
1
作者 梁国秀 李莉莎 +2 位作者 王蓉 阳先花 朱艳 《黑龙江医学》 2013年第9期817-818,共2页
目的探讨5-FU宫颈局部多点注射联合TP方案用于晚期宫颈癌新辅助化疗法的临床疗效、安全性及护理方法。方法选取2007-10~2012-03间我科收治的60例局部宫颈晚期癌患者,随机分为实验组与对照组。对照组22例单用TP方案,实验组38例给予5-FU... 目的探讨5-FU宫颈局部多点注射联合TP方案用于晚期宫颈癌新辅助化疗法的临床疗效、安全性及护理方法。方法选取2007-10~2012-03间我科收治的60例局部宫颈晚期癌患者,随机分为实验组与对照组。对照组22例单用TP方案,实验组38例给予5-FU宫颈局部多点注射联合TP方案,观察两组的临床疗效及并发症发生率。结果 5-FU宫颈局部多点注射联合TP方案用于晚期宫颈癌的新辅助化疗法优于单用TP方案。结论正确的专科护理是顺利完成治疗、预防并发症的关键。 展开更多
关键词 5-FU 宫颈局部多点注射 TP方案 宫颈晚期癌 新辅助化疗 护理
下载PDF
动静脉不同途径新辅助化疗对年轻局部晚期宫颈癌术后患者卵巢功能的影响 被引量:6
2
作者 陈滢 王晶 +1 位作者 杨赛花 童明 《医药导报》 CAS 2015年第3期344-346,共3页
目的评价年轻局部晚期宫颈癌术前动脉、静脉不同途径新辅助化学治疗(化疗)对术后卵巢功能的影响。方法采用回顾性研究,确诊为局部晚期子宫颈鳞状细胞癌并行宫颈癌根治术且术中保留双侧卵巢的年轻(手术年龄〈45岁)女患者38例,按照新... 目的评价年轻局部晚期宫颈癌术前动脉、静脉不同途径新辅助化学治疗(化疗)对术后卵巢功能的影响。方法采用回顾性研究,确诊为局部晚期子宫颈鳞状细胞癌并行宫颈癌根治术且术中保留双侧卵巢的年轻(手术年龄〈45岁)女患者38例,按照新辅助化疗途径分为A组(动脉介入栓塞化疗)20例,B组(静脉化疗)18例,每例均进行一疗程TP方案化疗[注射用紫杉醇脂质体135-175 mg·(m^2)^-1,顺铂50 mg·(m^2)^-1],术后行3个周期BOMP化疗。回顾性分析比较两组手术前后血清雌二醇(E2)、卵泡刺激素(FSH)、黄体生成素(LH)变化以评估卵巢功能。分别比较两组化疗前、化疗后2-3周(术前)、术后1个月及术后6个月的E2、FSH及LH水平。结果 A组化疗后2-3周(术前)及术后1个月E2水平较化疗前下降,FSH升高,差异有统计学意义(P〈0.05),B组各激素在不同时点比较均差异无统计学意义(P〉0.05),两组LH在不同时点及两组术后6个月与化疗前比较均差异无统计学意义(P〉0.05)。A组术前E2水平明显低于B组,其余两组间差异无统计学意义(P〉0.05)。随访中,无一例因卵巢转移复发。结论年轻局部晚期宫颈癌患者术前行动脉介入栓塞化疗对卵巢功能的影响是短暂、可逆的,术前静脉化疗对卵巢功能几无影响,宫颈癌根治术中保留双侧卵巢是保护年轻局部晚期宫颈癌患者内分泌功能安全有效的方法。 展开更多
关键词 新辅助化疗 宫颈 晚期/局部 卵巢功能
下载PDF
局部晚期宫颈鳞状细胞癌血清外泌体miR-17-5p表达及临床意义 被引量:3
3
作者 王洪伟 刘冰 +1 位作者 马建华 董志成 《临床肿瘤学杂志》 CAS 2022年第10期910-916,共7页
目的 探讨血清外泌体miR-17-5p在局部晚期宫颈鳞状细胞癌(LACSCC)放疗随访中的临床价值。方法 选择2014年1月至2018年12月于我院进行放疗的146例LACSCC患者作为研究对象,采用实时荧光定量PCR(q PCR)检测患者放疗前后的血清外泌体miR-17... 目的 探讨血清外泌体miR-17-5p在局部晚期宫颈鳞状细胞癌(LACSCC)放疗随访中的临床价值。方法 选择2014年1月至2018年12月于我院进行放疗的146例LACSCC患者作为研究对象,采用实时荧光定量PCR(q PCR)检测患者放疗前后的血清外泌体miR-17-5p水平,其他潜在血清生物标志物包括放疗前后鳞状细胞癌抗原(SCC-Ag)、基质金属蛋白酶(MMP)-1和MMP-2。无进展生存期(PFS)为主要终点,总生存期(OS)为次要终点。结果 LACSCC患者放疗后的血清外泌体miR-17-5p水平显著低于基线值(P<0.05)。高表达组年龄>60岁、体质量指数>24.9 kg/m^(2)、国际妇产科联盟分期在Ⅲ~Ⅳa期的LACSCC患者比例更高(P<0.05)。基线血清外泌体miR-17-5p表达升高与PFS、OS较短有关(P<0.05)。Cox风险比例回归模型分析,最大肿瘤直径、基线血清SCC-Ag和外泌体miR-17-5p水平均是PFS及OS的独立预测因子(P<0.05)。经受试者工作特征曲线分析,基线血清外泌体miR-17-5p联合SCC-Ag水平预测LACSCC患者局部治疗失败或远处转移的曲线下面积分别为0.803(95%CI:0.704~0.901)、0.832(95%CI:0.756~0.908),优于SCC-Ag单独预测价值。结论 血清外泌体miR-17-5p可能是预测LACSCC患者放疗后生存结局的重要生物标志物。 展开更多
关键词 局部晚期宫颈鳞状细胞 miR-17-5p 放疗 生存结局 血清样本
下载PDF
中晚期宫颈鳞癌患者治疗前外周血Treg计数分析 被引量:1
4
作者 郑雨薇 黄啸 +3 位作者 郭林 杨文韬 吴佳文 平波 《中国癌症杂志》 CAS CSCD 北大核心 2015年第4期241-246,共6页
背景与目的:中晚期宫颈鳞癌同期放化疗(concurrent chemoradiotherapy,CCRT)治疗前性价比高的疗效判断方法较有限,该研究拟通过检测治疗前外周血CD4+CD25+CD127Low/-调节性T细胞(regulatory T cells,Tregs)亚群计数及血清鳞癌抗... 背景与目的:中晚期宫颈鳞癌同期放化疗(concurrent chemoradiotherapy,CCRT)治疗前性价比高的疗效判断方法较有限,该研究拟通过检测治疗前外周血CD4+CD25+CD127Low/-调节性T细胞(regulatory T cells,Tregs)亚群计数及血清鳞癌抗原(squamous cell carcinoma antigen,SCC-Ag)水平,评价两者预测临床疗效的可行性。方法:采集44例ⅡB~ⅣA期宫颈鳞癌患者行CCRT治疗前的外周血标本,分别利用流式细胞免疫表型分析和酶联免疫法检测外周血CD4+CD25+CD127Low/-Treg计数及血清SCC-Ag水平。收集临床和病理资料,并统计检验2个指标对疗效的预测作用。结果:治疗前外周血CD4+CD25+CD127Low/-Treg计数在临床有效组低于无效组[(8.78±2.80)%vs(10.95±2.56)%,P〈0.05],血清SCC-Ag在不同临床疗效组间差异无统计学意义,且这2个指标之间未发现相关性(Spearman’rho=-0.093,P=0.540)。经受试者工作特征(receiver operating characteristic,ROC)曲线确定治疗前外周血CD4+CD25+CD127Low/-Treg及血清SCC-Ag最佳界值分别为9.76%与9.50 ng/m L。单因素分析显示,治疗前外周血CD4+CD25+CD127Low/-Treg计数(OR=1.901,95%CI:1.112~3.219,P=0.017)对CCRT疗效有预测作用,而血清SCC-Ag水平无预测作用(OR=0.998,95%CI:0.001~4.253,P=0.897)。多因素Logistic回归分析显示,治疗前外周血CD4+CD25+CD127Low/-Treg为独立的临床疗效预测因子(OR=3.115,95%CI:1.253~7.742,P=0.014)。结论:治疗前外周血CD4+CD25+CD127Low/-Treg计数用于中晚期宫颈鳞癌患者CCRT临床疗效预测具有可行性。 展开更多
关键词 晚期宫颈鳞状细胞 同期放化疗 调节性T细胞 血清鳞状细胞抗原
下载PDF
58例局部晚期宫颈癌综合治疗近期疗效 被引量:3
5
作者 吕瑞 张庆明 《甘肃医药》 2010年第4期410-412,共3页
目的:分析局部晚期宫颈癌经综合治疗后的近期疗效,以总结其特征,寻求更合理的治疗方案。方法:2004年3月至2007年12月我院收治局部晚期宫颈癌58例,术前一次介入及静脉化疗37例,其中6例加后装内照2~3次,每次5GY;9例仅采用后装内照2~3次... 目的:分析局部晚期宫颈癌经综合治疗后的近期疗效,以总结其特征,寻求更合理的治疗方案。方法:2004年3月至2007年12月我院收治局部晚期宫颈癌58例,术前一次介入及静脉化疗37例,其中6例加后装内照2~3次,每次5GY;9例仅采用后装内照2~3次,每次5GY;其余12例采用术中髂内动脉及静脉化疗。非局部晚期组403例中,术前介入化疗者173例;术前后装放疗者21例;术中动脉化疗者126例;单纯手术者83例。通过术前疗效的判定及术后随访复发率的分析来评定综合治疗的效果。结果:①局部晚期组近期疗效:单纯介入治疗者CR16.2%、PR21.6%、NC51.4%、PD10.8%,介入+后装者CR0.0%、PR16.7%、NC83.3、4%、PD0.0%,后装者CR11.1%、PR22.2%、NC66.7%、PD0.0%。②非局部晚期组近期疗效:单纯介入治疗者CR27.2%、PR41.6%、NC16.8%、PD2.9%,后装者CR28.6%、PR67.1%、NC14.3%、PD0.0%。两组比较P<0.05。③近期复发率:所有病例实施了手术为主附加各不相同的综合治疗,局部晚期组因存在更多高危险因素,采用更积极、更繁杂的治疗手段,但两组在近期(1年)复发率存在差异。局部晚期组治疗后1年内发现复发者17例(29.3%),非局部晚期组1年内发现复发21例(0.52%),P<0.05。结论:局部晚期宫颈癌虽经临床上多学科综合治疗,但较同期别非局部晚期宫颈癌具有疗效差,近期复发率高,预后不良的特点。 展开更多
关键词 宫颈局部晚期 近期疗效
下载PDF
贝伐珠单抗联合单药化疗治疗晚期宫颈腺癌的临床分析
6
作者 刘莹 《中国卫生标准管理》 2016年第24期81-83,共3页
目的探讨贝伐珠单抗联合单药化疗治疗晚期宫颈腺癌的临床疗效。方法抽取晚期宫颈腺癌患者68例为研究对象,随机分组,治疗组(n=34)采取贝伐珠单抗联合吉西他滨化疗,对照组(n=34)单纯采取吉西他滨化疗,对比两组疗效。结果治疗组生活质量评... 目的探讨贝伐珠单抗联合单药化疗治疗晚期宫颈腺癌的临床疗效。方法抽取晚期宫颈腺癌患者68例为研究对象,随机分组,治疗组(n=34)采取贝伐珠单抗联合吉西他滨化疗,对照组(n=34)单纯采取吉西他滨化疗,对比两组疗效。结果治疗组生活质量评分是(83.4±6.3)分,治疗有效率是58.8%;对照组生活质量评分是(65.8±7.1)分,治疗有效率是32.4%;两组对比差异有统计学意义(P<0.05)。结论贝伐珠单抗联合单药化疗治疗晚期宫颈腺癌的临床疗效肯定。 展开更多
关键词 贝伐珠单抗 单药化疗 晚期宫颈
下载PDF
5FU局部多点注射联合TP方案用于宫颈局部晚期癌术前新辅助化疗的临床研究 被引量:4
7
作者 李莉莎 甘海英 +3 位作者 林琼 芦冬兰 刘丹 安云婷 《中国妇幼保健》 CAS 北大核心 2013年第5期873-875,共3页
目的:探讨5-FU宫颈局部多点注射联合TP方案用于晚期宫颈癌新辅助化疗的疗效和安全性。方法:选择2007年10月~2012年3月住院治疗的60局部晚期宫颈癌患者,分为实验组与对照组,实验组38例给予5-FU局部多点联合TP方案术前新辅助化疗后手术,... 目的:探讨5-FU宫颈局部多点注射联合TP方案用于晚期宫颈癌新辅助化疗的疗效和安全性。方法:选择2007年10月~2012年3月住院治疗的60局部晚期宫颈癌患者,分为实验组与对照组,实验组38例给予5-FU局部多点联合TP方案术前新辅助化疗后手术,对照组22例给予TP方案后行手术治疗。对两组术后病理、毒副反应、临床疗效进行比较。结果:实验组患者CR、PR分别为(12,31.58%)、(21,55.26%),总有效率为(33,86.84%)。对照组患者CR、PR分别为(2,9.1%)、(11,50%),总有效率为(13,59.1%)。毒副反应两组相当,经对症处理后都能耐受。结论:5-FU宫颈局部多点注射联合TP方案进行术前新辅助化疗后患者最大肿瘤直径缩小明显,毒副反应并未明显增加,是一种安全有效的治疗方法。 展开更多
关键词 5-FU TP方案局部多点注射宫颈局部晚期新辅助化疗
原文传递
Pharmacokinetic comparison between ultraselection of uterine artery and peripheral vein chemotherapy of carboplatin in cervical cancer
8
作者 Wei Wang Chunlin Chen +3 位作者 Ping Liu Ben Ma Cui Liu Lani Chen 《The Chinese-German Journal of Clinical Oncology》 CAS 2009年第5期251-254,共4页
Objective:The present study is to compare pharmacokinetics difference of carboplatin by using ultraselection uterine artery with by using peripheral vein in cervical cancer.Methods:Thirteen patients with locally advan... Objective:The present study is to compare pharmacokinetics difference of carboplatin by using ultraselection uterine artery with by using peripheral vein in cervical cancer.Methods:Thirteen patients with locally advanced cervical cancer who had been proved by pathobiology were randomly divided into two groups:the ultraselection uterine artery group(group A, n = 6) and the peripheral vein(group B, n = 7).Carboplatin was administered by infusing into artery or vein in both groups at the dosage of 300 mg/m2.Tissues from the cervical tumor were collected at different times after infusion in both groups and then analyzed.Results:The peak concentration of platinum in tumor tissue was about 2.79 times higher in group A than that of group B(P < 0.05).The platinum concentrations in tumor in group A reached its peak levels immediately after infusion.But, group B had delayed time.While, for the time point of 0 min, when the administration finished immediately, the platinum concentration in tumor was significantly higher when compared with group B(P < 0.05).The tumor tissue area under the concentration(AUC) of carboplatin was about 2 times higher in group A than that of group B(P < 0.05).Conclusion:We observed the pharmacological advantages of chemotherapy by using ultraselection uterine artery administration of chemotherapeutic agent carboplatin in tumor tissue which provided theoretical basis and laboratory parameters of the intra-arterial chemotherapy for gynecologic malignancy. 展开更多
关键词 cervical cancer uterine artery VEIN intra-arterial infusion chemotherapy peak value of platinum area underthe concentration time curve
下载PDF
Neoadjuvant intra-arterial infusion chemotherapy followed by surgery in patients with locally advanced cervical cancer
9
作者 Qin Wu Yi Zhang 《The Chinese-German Journal of Clinical Oncology》 CAS 2009年第9期537-540,共4页
Objective: The aim of this study was to investigate the role of preoperative neoadjuvant intra-arterial infusion chemotherapy (NAIC) in treating locally advanced cervical caner. Methods: Nineteen locally advanced ... Objective: The aim of this study was to investigate the role of preoperative neoadjuvant intra-arterial infusion chemotherapy (NAIC) in treating locally advanced cervical caner. Methods: Nineteen locally advanced cervical cancer (LACC) patients from November 2003 to November 2005 were analyzed retrospectively. NAIC was administrated 2 courses every 2 weeks using a combination of 30 mg/m^2 bleomycin and 50 mg/m^2 cisplatin via bilateral femur artedes. The response to NAIC was assessed by pelvic examination and imaging diagnostics and histological analysis. Two weeks after NAIC radical hysterectomy with pelvic lymphadenectomy was performed. Results: Radical hysterectomy with pelvic lymphadenectomy were performed in 18 patients successfully. The mean tumor reduction rate was 73.04%. The overall clinical response rate of NAIC was 84.2% with 2 complete responses and 16 partial responses. Only 1 nonresponder. Six of 7 cases who had parametrial infiltration had a absence after chemotherapy, no significant change was observed in 1 case who followed by radiotherapy. Multivariate logistic regression analysis indicated that tumor volume prior to treatment was determining factor affecting the efficacy of NAIC in LACC. Conclusion: pre-operative NAIC inhibited the growth of LACC, minimized the size, eliminate effectively the pathologic dsk factors in the pelvic cavity, to improve the operability in cervical cancer patients with stage lib or above, considered inoperable. 展开更多
关键词 locally advanced cervical cancer (LACC) neoadjuvant intra-arterial infusion chemotherapy (NAIC) SURGERY
下载PDF
Recent achievements and acute toxicity after TP concurrent chemoradiotherapy for the advanced cervical cancer
10
作者 Qinghua Ke Shiqiong Zhou +4 位作者 Wei Du Yong Lei Min Huang Fei Luo Jiyuan Yang 《The Chinese-German Journal of Clinical Oncology》 CAS 2012年第7期411-413,共3页
Objective: The aim of our study was to investigate the early outcome of the taxotere and cisplatin chemora- diotherapy to the advanced cervical cancer. Methods: Fifty-six cases with cervical cancer (FIGO lib to IVa... Objective: The aim of our study was to investigate the early outcome of the taxotere and cisplatin chemora- diotherapy to the advanced cervical cancer. Methods: Fifty-six cases with cervical cancer (FIGO lib to IVa) were divided randomly into two groups in the oncology hospital of Jingzhou from September 2009 to October 2010, radiotherapy alone (28 cases) and radiation plus chemotherapy (TP) group. There was no difference of radiotherapy between the two groups, the RT + C cases who accepted TP regimen during the radiation, and DDP once weekly injection of vain, according to 20 mg/m2 and taxotere once weekly i.v. according to 35 mg/m2. These regimen were given for 4-5 weeks, and some medicine for vomit- ing was given to the RT + C cases. Two groups were received an oral medicine MA 160 mg every day during the treatment. Results: The early outcome: the complete remission rate was 64.3% and partial remission rate was 35.7% in RT + C. The complete remission rate was 32.1% and partial remission rate was 39.3% in RT. The total response rate and complete remis- sion of RT + C group was higher than that of the RT group. There was significant difference between the two groups. In RT + C group, 1-year survive rate was 100.00% (28/28); in RT group, 1-year survive rate was 85.71% (24/28). There was significant difference between the two groups (X2 = 4.31 〉 3.84, P 〈 0.05). Conclusion: The taxotere and cisplatin chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and the adverse effect are raised, but that can be endured. 展开更多
关键词 cervical cancer TAXOTERE CISPLATIN CHEMORADIOTHERAPY
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部